Location History:
- Shanghai, CN (2010 - 2014)
- Pudong District, CN (2015)
Company Filing History:
Years Active: 2010-2015
Title: Innovations of Shengbin Li in SGLT2 Inhibitors
Introduction
Shengbin Li is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of pharmaceuticals. He holds a total of six patents, focusing primarily on processes that enhance the preparation of SGLT2 inhibitors. His work has the potential to impact the treatment of various diseases related to glucose regulation.
Latest Patents
One of Shengbin Li's latest patents involves processes for the preparation of SGLT2 inhibitors. This invention provides methods for creating complexes that are useful in purifying compounds that inhibit the sodium-dependent glucose cotransporter SGLT. The processes he developed can reduce the number of steps required to obtain the target compounds, and the complexes formed are typically provided in a crystalline form. Another notable patent includes benzylbenzene derivatives and methods of use. This invention presents compounds that have an inhibitory effect on SGLT, along with pharmaceutical compositions, methods for preparing these compounds, synthetic intermediates, and methods for using them, either independently or in combination with other therapeutic agents, to treat diseases affected by SGLT inhibition.
Career Highlights
Throughout his career, Shengbin Li has worked with various companies, including Theracos, Inc. and Theracos Sub, LLC. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to the development of effective treatments.
Collaborations
Shengbin Li has collaborated with notable coworkers such as Yuelin Wu and Yuanwei Chen. Their combined efforts have further advanced the research and development of SGLT2 inhibitors.
Conclusion
Shengbin Li's innovative work in the field of SGLT2 inhibitors showcases his dedication to improving pharmaceutical processes and treatments. His patents reflect a commitment to enhancing the efficiency of drug development, which could lead to better health outcomes for patients.